Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low molecular weight heparin sodium for sepsis-associated acute gastrointestinal injury
ChiCTR2300072241Phase 4Completed
- Sponsor
- The First Hospital of Lanzhou University
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of low molecular weight heparin calcium in acute gastrointestinal injury (AGI) and sepsis (2 arms), sponsored by The First Hospital of Lanzhou University. Primary endpoints: heparanase, syndecan-1 and 7 more. Started Mar 2022; status: completed.
02
Drugs
low molecular weight heparin calcium
03
Conditions
acute gastrointestinal injury (AGI)sepsis
Beyond the preview
Go deeper on ChiCTR2300072241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072241.